AU2015312430B2 - Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof - Google Patents

Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof Download PDF

Info

Publication number
AU2015312430B2
AU2015312430B2 AU2015312430A AU2015312430A AU2015312430B2 AU 2015312430 B2 AU2015312430 B2 AU 2015312430B2 AU 2015312430 A AU2015312430 A AU 2015312430A AU 2015312430 A AU2015312430 A AU 2015312430A AU 2015312430 B2 AU2015312430 B2 AU 2015312430B2
Authority
AU
Australia
Prior art keywords
levodopa
carbidopa
dopamine
inhibitor
entacapone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2015312430A
Other languages
English (en)
Other versions
AU2015312430A1 (en
Inventor
Roger Bolsoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lobsor Pharmaceuticals AB
Original Assignee
Lobsor Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE1451034A external-priority patent/SE538425C2/en
Application filed by Lobsor Pharmaceuticals AB filed Critical Lobsor Pharmaceuticals AB
Publication of AU2015312430A1 publication Critical patent/AU2015312430A1/en
Application granted granted Critical
Publication of AU2015312430B2 publication Critical patent/AU2015312430B2/en
Priority to AU2020239682A priority Critical patent/AU2020239682B2/en
Priority to AU2022200291A priority patent/AU2022200291B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015312430A 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof Active 2038-09-01 AU2015312430B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020239682A AU2020239682B2 (en) 2014-09-04 2020-09-23 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
AU2022200291A AU2022200291B2 (en) 2014-09-04 2022-01-18 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1451034A SE538425C2 (en) 2014-09-04 2014-09-04 Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
SE1451034-1 2014-09-04
SE1550344-4 2015-03-24
SE1550344 2015-03-24
PCT/SE2015/050939 WO2016036308A1 (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020239682A Division AU2020239682B2 (en) 2014-09-04 2020-09-23 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof

Publications (2)

Publication Number Publication Date
AU2015312430A1 AU2015312430A1 (en) 2017-03-30
AU2015312430B2 true AU2015312430B2 (en) 2020-06-25

Family

ID=55440194

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015312430A Active 2038-09-01 AU2015312430B2 (en) 2014-09-04 2015-09-04 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
AU2020239682A Active 2038-09-01 AU2020239682B2 (en) 2014-09-04 2020-09-23 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
AU2022200291A Active 2038-09-01 AU2022200291B2 (en) 2014-09-04 2022-01-18 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020239682A Active 2038-09-01 AU2020239682B2 (en) 2014-09-04 2020-09-23 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
AU2022200291A Active 2038-09-01 AU2022200291B2 (en) 2014-09-04 2022-01-18 Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof

Country Status (16)

Country Link
US (5) US10071069B2 (enExample)
EP (3) EP4356907A1 (enExample)
JP (2) JP6622310B2 (enExample)
CN (1) CN107072973A (enExample)
AU (3) AU2015312430B2 (enExample)
CA (2) CA3175785A1 (enExample)
DK (2) DK3782617T3 (enExample)
ES (2) ES2973289T3 (enExample)
FI (1) FI3782617T3 (enExample)
HR (2) HRP20210025T1 (enExample)
HU (2) HUE066097T2 (enExample)
PL (2) PL3782617T3 (enExample)
PT (2) PT3782617T (enExample)
RS (1) RS65337B1 (enExample)
SI (2) SI3188725T1 (enExample)
WO (1) WO2016036308A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
PT3782617T (pt) 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
WO2016083863A1 (en) * 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2017177262A1 (en) * 2016-04-11 2017-10-19 University Of Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
JP2019523249A (ja) * 2016-07-20 2019-08-22 アッヴィ・インコーポレイテッド レボドパ及びカルビドパ腸管ゲル、並びに使用方法
EP3275433A1 (en) 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
MX387370B (es) * 2017-02-13 2025-03-18 Elanco Animal Health Gmbh Composición líquida que contiene pradofloxacina.
CN111902136A (zh) * 2017-12-28 2020-11-06 瑞璞鑫(苏州)生物科技有限公司 用于预防和/或治疗肥胖症和相关代谢性疾病的托卡朋
AU2019237857B2 (en) * 2018-03-23 2024-11-21 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
EP3593819A1 (en) 2018-07-10 2020-01-15 Medday Pharmaceuticals Compositions for therapeutic uses containing 5-htp and carbidopa
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
WO2020131671A1 (en) 2018-12-18 2020-06-25 Eli Lilly And Company Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
JP7506371B2 (ja) * 2020-01-20 2024-06-26 国立大学法人浜松医科大学 ドーパミン減少抑制剤
JP2023517690A (ja) * 2020-03-13 2023-04-26 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 微粉化オピカポン
CN111643493B (zh) * 2020-05-26 2023-01-10 上海京新生物医药有限公司 一种高浓度左旋多巴制剂及其制备方法及其应用
EP4200280B1 (en) 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
WO2022158991A1 (en) * 2021-01-20 2022-07-28 Bial-Portela & Ca., S.A. Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa
CN117731627B (zh) * 2023-12-20 2026-04-10 重庆迈川医药科技有限公司 一种多巴丝肼片及其制备方法和应用
WO2025162373A1 (en) * 2024-01-30 2025-08-07 National Institute Of Biological Sciences, Beijing Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway
WO2026155658A1 (en) * 2025-01-15 2026-07-23 I3S - Instituto De Investigação E Inovação Em Saúde, Associação Low-dose dopaminergic drugs to delay the progression of spinocerebellar ataxia type 3 and alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098661A1 (en) * 2008-02-06 2009-08-13 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
US20130253056A1 (en) * 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004348D0 (en) 1990-02-27 1990-04-25 Orion Yhtymae Oy New use of catechol derivatives and their physiologically acceptable salts and esters
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
CA2350304A1 (en) * 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing l-dopa ethyl ester
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20100221321A1 (en) 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
MXPA06002344A (es) 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20060222703A1 (en) 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
KR20090057349A (ko) 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파／칼비도파의 ２４시간의 장기간 장내투여
EP2104424A4 (en) 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
PT3192500T (pt) * 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
DK2640358T3 (en) 2010-11-15 2018-04-16 Neuroderm Ltd CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA-DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS THEREOF
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
HUE056006T2 (hu) 2013-03-13 2022-01-28 Neuroderm Ltd Kombináció Parkinson-kór kezelésére
SE538425C2 (en) 2014-09-04 2016-06-21 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
PT3782617T (pt) 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098661A1 (en) * 2008-02-06 2009-08-13 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
US20130253056A1 (en) * 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NYHOLM, D. et al., "Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial", Eur. J. Neurol., (2012-06), vol. 19, no. 6, pages 820 - 826 *
SOLLA PAOLO et al., "Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo", Neuropsychiatric disease and treatment, (20100000), vol. 6, pages 4 83 - 490 *

Also Published As

Publication number Publication date
JP6622310B2 (ja) 2019-12-18
PL3188725T3 (pl) 2021-08-02
US20220362193A1 (en) 2022-11-17
CA2959307C (en) 2023-03-28
CA2959307A1 (en) 2016-03-10
HUE052857T2 (hu) 2021-05-28
AU2020239682A1 (en) 2020-10-15
SI3188725T1 (sl) 2021-04-30
SI3782617T1 (sl) 2024-04-30
ES2973289T3 (es) 2024-06-19
EP3188725A4 (en) 2018-04-25
HRP20240314T1 (hr) 2024-05-24
FI3782617T3 (fi) 2024-03-13
AU2015312430A1 (en) 2017-03-30
DK3188725T3 (da) 2021-01-18
HUE066097T2 (hu) 2024-07-28
US20210023033A1 (en) 2021-01-28
US20170231937A1 (en) 2017-08-17
EP3782617A1 (en) 2021-02-24
US10786472B2 (en) 2020-09-29
PT3782617T (pt) 2024-02-29
DK3782617T3 (da) 2024-03-04
PL3782617T3 (pl) 2024-06-24
JP2017527623A (ja) 2017-09-21
PT3188725T (pt) 2021-01-27
EP3782617B1 (en) 2024-01-03
AU2022200291B2 (en) 2024-01-25
CA3175785A1 (en) 2016-03-10
US10071069B2 (en) 2018-09-11
ES2844500T3 (es) 2021-07-22
RS65337B1 (sr) 2024-04-30
US12156858B2 (en) 2024-12-03
WO2016036308A1 (en) 2016-03-10
US11413262B2 (en) 2022-08-16
HRP20210025T1 (hr) 2021-03-05
JP6889231B2 (ja) 2021-06-18
EP3188725B1 (en) 2020-10-28
EP4356907A1 (en) 2024-04-24
AU2020239682B2 (en) 2021-12-23
US20250041257A1 (en) 2025-02-06
JP2020045353A (ja) 2020-03-26
CN107072973A (zh) 2017-08-18
AU2022200291A1 (en) 2022-02-10
US20180338944A1 (en) 2018-11-29
EP3188725A1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
US12156858B2 (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
US10555922B2 (en) Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
US20250213518A1 (en) Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
JP2021519272A5 (enExample)
HK40110793A (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
HK40044749A (en) Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone
HK40044749B (en) Pharmaceutical gel compositions comprising levodopa, carbidopa and entacapone

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: LECIGON LEVODOPA

Filing date: 20230901

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: LECIGON LEVODOPA

Filing date: 20230901

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: LECIGON LEVODOPA

Filing date: 20230901

Extension date: 20380901